GLPwatch
Byetta for Smoking cessation
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCByetta (exenatide) is not FDA-approved for smoking cessation, and any use for this purpose is off-label or investigational. The listed research includes pilot trials and study protocols exploring exenatide as an adjunct to nicotine patches for smoking cessation and weight management.
AI summary of the sources below.
| Drug | Byetta (exenatide) |
|---|---|
| Condition | Smoking cessation |
| Approval status | Investigational / off-label |
| Research papers | 3 |
Byetta is not FDA-approved for smoking cessation; the research below reflects investigational or off-label study only.
Research on exenatide for smoking cessation (3)
- Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.
- Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial.
- Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial.